Bing

SEARCH HISTORY

Today’s Gospel: RegMed stocks are still sputtering along … in the dog days of summer! Dendreon (DNDN) is leading the pack followed by Verastem (VSTM) with, BioMimetic (BMTI), Tengion (TNGN), and Osiris (OSIR) and even … Athersys (ATHX). It’s a ...
Proactive Investors UK · 7/16/2012
Athersys, Inc. operates as a biopharmaceutical company, which is engaged in the discovery and development of therapies designed to extend and enhance the quality of human life.It establishes product development programs through the application of ...
4 Traders · 6/26/2015
Athersys, Inc. (NASDAQ:ATHX) [Trend Analysis] and Chugai Pharmaceutical Co., Ltd. have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke …
emarketsdaily.com · 3/3/2015
More from Bing News
Uniqure NV (NASDAQ:QURE)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer in a research report issued on Monday. They currently have a $47.00 price target on the stock. Oppenheimer’s price target points to a ...
Ticker Report · 6/23/2015
BOSTON (MarketWatch) — After years of being swatted about like ping-pong balls, are stem-cell stocks now worth a second look? Perhaps no other medical subsector has had to endure as much volatility as the fledgling stem-cell space, where even the …
Market Watch · ByVal Brickates · 7/13/2011
Shares withheld from the quarterly vesting of a June 2013 restricted stock unit award related to the minimum tax withholding obligation. Shares sold pursuant to a predefined Rule 10b5-1 trading plan for tax and planning purposes related to the quarterly ...
INSIDER MONKEY · 6/22/2015
Today after the close the following companies were scheduled to report earnings: IRG, HIL, JMBA, OMED, MED, TEAR, ANAC, FF, FXCM, GST, KTOS, LOCO, ATHX, EGY, KRO, INGN, FTD, RMAX, ARO, ULTA, ZUMZ, IRET, PPHM Other notable movers on …
Briefing Live Market Analysis · 3/12/2015
Reni Benjamin looks at some of his favorite biotech stocks working in regenerative medicine. Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center.
Kaptiall WIre · 2/13/2014
MINYANVILLE ORIGINAL The long-awaited, even miraculous breakthrough represents a major evolution in stem cell research that could spur interest in the sector. Now the world watches as great news for the ALS community continues to emerge. Up until …
Minyanville · 8/31/2012
CLEVELAND, April 8, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (ATHX) announced today that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal ...
Yahoo New Zealand · 4/8/2015